ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis

ClinicalTrials.gov ID: NCT03935217

Public ClinicalTrials.gov record NCT03935217. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 11:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Multi-center, Prospective, Randomized, Placebo-Controlled, Delayed Treatment, Double-Blind Study to Evaluate the Effectiveness and Safety of a Single Oral Dose of Solosec® for the Treatment of Trichomoniasis

Study identification

NCT ID
NCT03935217
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Lupin Research Inc
Industry
Enrollment
147 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Secnidazole Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 22, 2019
Primary completion
Mar 1, 2020
Completion
Mar 24, 2020
Last update posted
Oct 3, 2023

2019 – 2020

United States locations

U.S. sites
11
U.S. states
9
U.S. cities
10
Facility City State ZIP Site status
Site 1007 Birmingham Alabama 35294
Site 1003 North Miami Florida 33161
Site 1014 Chicago Illinois 60605
Site 1013 Jackson Mississippi 39216
Site 1009 Lawrenceville New Jersey 08648
Site 1008 Chapel Hill North Carolina 27599
Site 1004 Fayetteville North Carolina 28304
Site 1011 Charleston South Carolina 29425
Site 1001 Memphis Tennessee 38104
Site 1002 Memphis Tennessee 38120
Site 1006 Virginia Beach Virginia 23456

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03935217, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 3, 2023 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03935217 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →